Financial PerformanceAnalyst lowered the price target to $125 from $137 due to lower comp group multiples and slightly reduced 2025 revenue expectations.
Product Launch DelaysPlans to delay the Zio MCT regulatory filing until 3Q25, taking approximately $10M out of 2025 sales.
Regulatory IssuesThe company did not provide an update on resolving its outstanding regulatory notices, such as 483 observations and the Zio AT warning letter, which could pose a risk.